Comparative Assessment of the Efficacy of Liposomal Xymedon and Its Aqueous Solution in Correction of LPO and Antioxidant Protection in the Liver of Rats with Transplanted Neoplasia Treated with Liposomal Antitumor Drugs.

We studied the effect of liposomal xymedon (50 and 100 mg/kg) on LPO and antioxidant protection parameters in the liver of rats with Walker-256 carcinoma treated with a liposomal combination of doxorubicin (4 mg/kg) and cyclophosphamide (45 mg/kg) (once intravenously on day 11 after tumor cell transplantation). Xymedon (in liposomes and as an aqueous solution) was administered intravenously for 5 days starting from day 11 of the experiment. The parameters of LPO and antioxidant protection were assessed on days 3 and 7 after chemotherapy. Intensification of LPO in the liver was observed on day 3 after the administration of liposomal cytostatics in comparison with the use of their aqueous solutions. The advantage of liposomal xymedon over its aqueous solution lies in the development of a hepatoprotective effect at the minimum tested dose (50 mg/kg), which is manifested by a decrease in the levels of diene conjugates and MDA with a balanced increase in SOD and catalase activities in the liver, as well as the prevention of diarrhea associated with the use of the aqueous xymedon solution at a dose of 100 mg/kg.